This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-08. Anything still debated is marked as such rather than presented as settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
The sessions were produced by Joe Foster, but McGee, unsatisfied with Foster's work, remixed the A-side, although the B-side, a cover version of Syd Barrett's "Vegetable Man", remained credited to Foster. The band were gaining increasing attention from the music press at this time with Neil Taylor of the NME describing them as "the best band in the world". Dalglish left in November 1984 after a dispute over money and was replaced shortly afterwards by Gillespie who had also formed Primal Scream two years earlier in 1982. "Upside Down" topped the UK Indie Chart in February 1985 and then again in March and stayed on the chart for 76 weeks, selling around 35,000 copies in total, making it one of the biggest-selling indie singles of the 1980s. Playing in front of small audiences, during early shows the Mary Chain performed very short gigs, typically fueled by amphetamines and lasting around 20 minutes, and played with their backs to the audience, refusing to speak to them. In late December 1984, the band performed as part of the ICA Rock Week. During their performance, bottles were thrown on stage, with press reports exaggerating events and claiming that there had been a riot, and national newspaper The Sun running a story on the band concentrating on violence and drugs, the band attracting the tag "The new Sex Pistols". That led several local councils to ban the band from performing in their area.
== Function == The architecture of a dry shipper encompasses two primary components: an internal canister and an external protective shell. The inner canister, designed to hold biological specimens, is positioned within the vapor phase of the liquid nitrogen. This configuration ensures that the specimens are maintained at temperatures below -150 °C (302 °F) for prolonged periods. A distinctive feature of dry shippers is their ability to avert direct contact between samples and liquid nitrogen, reducing risks of contamination and ensuring consistent cryogenic conditions during transit.
=== Foundations of organic synthesis and the origin of life === Until the 19th century, there was considerable acceptance of the theory of spontaneous generation, the idea that "lower" animals, such as insects or rodents, arose from decaying matter. However, several experiments in the 19th century – particularly Louis Pasteur's swan neck flask experiment in 1859 — disproved the theory that life arose from decaying matter. Charles Darwin published On the Origin of Species that same year, describing the mechanism of biological evolution. While Darwin never publicly wrote about the first organism in his theory of evolution, in a letter to Joseph Dalton Hooker, he speculated:But if (and oh what a big if) we could conceive in some warm little pond with all sorts of ammonia and phosphoric salts, light, heat, electricity etcetera present, that a protein compound was chemically formed, ready to undergo still more complex changes [...]"
Intentional burial, particularly with grave goods, may be one of the earliest detectable forms of religious practice since, as Philip Lieberman suggests, it may signify a "concern for the dead that transcends daily life". Evidence points to the Neanderthals as the first human species known to practice burial behavior and to intentionally bury their dead; they did so using shallow graves furnished with stone tools and animal bones. Exemplary sites include Shanidar in Iraq, Kebara Cave in Israel and Krapina in Croatia. Some scholars, however, argue that such "buried" bodies may have been disposed of for secular reasons. Though there is ongoing debate regarding the reliability of the dating method, some scholars believe the earliest human burial dates back 100,000 years. Archeological expeditions have discovered human skeletal remains stained with red ochre in the Skhul cave at Qafzeh in Israel. A variety of grave goods were present at the site, including the mandible of a wild boar in the arms of one of the skeletons. The remains of a 3-year-old child at Panga ya Saidi cave in Kenya dating to 78,000 years ago also show signs suggestive of a burial, such as the digging of a pit, laying of the body in a fetal position and intentional rapid covering of the corpse. In ancient Egypt, burial customs developed during the Predynastic period. Round graves with one pot were used in the Badarian Period (4400–3800 B.C.E.), continuing the tradition of Omari and Maadi cultures. Archeologists refer to unmarked prehistoric cemeteries using the neutral term "grave field".
==== Enzyme-linked immunosorbent assay ==== The enzyme-linked immunosorbent assay (ELISA) technique used for the analysis of YTXs is a recently developed method by Briggs et al. This competitive, indirect immunoassay uses polyclonal antibodies against YTX to determine its concentration in the sample. The assay is commercially available, and is a rapid technique for the analysis of YTXs in shellfish, algal cells, and culture samples. ELISA has several advantages: it is very sensitive, has a limit of quantification of 75 μg/kg, is relatively cheap, and is easy to carry out. The major disadvantage to this method is it cannot differentiate between the different YTX analogues and takes a long time to generate results.
Sources: en.wikipedia.org
=== 1979 === 5 August: Alison Chambers (16). Chambers had been placed into foster care at the age of 14 and had repeatedly absconded from Jordan's Brook House. She became acquainted with the Wests in mid-1979, and Fred later claimed to his solicitor that Chambers had died as a result of Rose becoming "too bloody vicious" with her. Her dismembered body, missing several bones and with a leather belt looped beneath her jaw and tied at the top of her head, was buried in the garden of Cromwell Street. This was the final murder where a definite sexual motive was established.
Once the food is in the digestive cavity, gland cells in the gastroderm release enzymes that reduce the prey to slurry, usually within a few hours. This circulates through the digestive cavity and, in colonial cnidarians, through the connecting tunnels, so that gastroderm cells can absorb the nutrients. Absorption may take a few hours, and digestion within the cells may take a few days. The circulation of nutrients is driven by water currents produced by cilia in the gastroderm or by muscular movements or both, so that nutrients reach all parts of the digestive cavity. Nutrients reach the outer cell layer by diffusion or, for animals or zooids such as medusae which have thick mesogleas, are transported by mobile cells in the mesoglea. Indigestible remains of prey are expelled through the mouth. The main waste product of cells' internal processes is ammonia, which is removed by the external and internal water currents.
June 25 2026 Utah wildfires: Utah Governor Spencer Cox announces a state of emergency and temporary restrictions on fireworks through the Fourth of July weekend until July 5 due to ongoing wildfires in the state, including the Cottonwood Fire. In Mullin v. Al Otro Lado, the U.S. Supreme Court rules 6–3 that migrants stopped on the Mexican side of the U.S.–Mexico border have not "arrived in the United States" for the purposes of federal immigration law, allowing the federal government to revive its "metering" policy for asylum seekers at border crossings. Florida Governor Ron DeSantis confirms that the Alligator Alcatraz detention center in Ochopee, Florida, will close operations, a year after it opened. June 26 Iran war: Trump accuses Iran of violating the truce with the US by launching drone attacks on ships in the Hormuz. The United States Central Command later announces that in retaliation to the alleged truce violations, the US hit Iranian missile and drone storage facilities, as well as coastal radar stations. Former national security adviser John Bolton pleads guilty to improperly retaining classified material. Flash floods hit Kentucky, leaving four dead. June 27 Iran war: The US military announces that it struck Iranian military surveillance infrastructure, communication systems, air defense sites, drone storage facilities, and minelayer capabilities at the commander-in-chief's direction in retaliation for an alleged Iranian attack against a ship in the Hormuz.
From Greek βίος (bíos) 'life', (from Proto-Indo-European root *gwei-, to live) and λογία (logia) 'study of'. The compound appears in the title of Volume 3 of Michael Christoph Hanow's Philosophiae naturalis sive physicae dogmaticae: Geologia, biologia, phytologia generalis et dendrologia, published in 1766. The term biology in its modern sense appears to have been introduced independently by Thomas Beddoes (in 1799), Karl Friedrich Burdach (in 1800), Gottfried Reinhold Treviranus (Biologie oder Philosophie der lebenden Natur, 1802) and Jean-Baptiste Lamarck (Hydrogéologie, 1802).
Sources: en.wikipedia.org
The caesium, precipitated with ferric ferrocyanide (Prussian blue) would be the only waste requiring special burial sites. The aim is to get annual exposure from the contaminated environment down to 1 millisievert (mSv) above background levels. The most contaminated area where radiation doses are greater than 50 mSv/year must remain off-limits, but some areas that are currently less than 5 mSv/year may be decontaminated, allowing 22,000 residents to return.
The Fascism and Freedom Movement – National Socialist Party (Italian: Movimento Fascismo e Libertà – Partito Socialista Nazionale, MFL–PSN), or simply Fascism and Freedom Movement, is an Italian fascist political party formed on 25 July 1991 by Giorgio Pisanò.
They went down to the Fourth Division again in 1972, and this time stayed down for seven seasons, finally returning to the Third Division in 1979. Two years later, they went up again and quickly established themselves as a decent Second Division side throughout the 1980s, although they still failed to clinch that elusive First Division place, despite the introduction of the play-offs in the second half of the decade, which gave teams finishing as low as fifth and eventually sixth the chance of winning promotion.
Substances that have the ability to reduce other substances (cause them to gain electrons) are said to be reductive or reducing and are known as reducing agents, reductants, or reducers. The reductant transfers electrons to another substance and is thus itself oxidized. Because it donates electrons, the reducing agent is also called an electron donor. Electron donors can also form charge transfer complexes with electron acceptors. The word reduction originally referred to the loss in weight upon heating a metallic ore such as a metal oxide to extract the metal. In other words, ore was "reduced" to metal. Antoine Lavoisier demonstrated that this loss of weight was due to the loss of oxygen as a gas. Later, scientists realized that the metal atom gains electrons in this process. The meaning of reduction then became generalized to include all processes that involve a gain of electrons. Reducing equivalent refers to chemical species that transfer the equivalent of one electron in redox reactions. The term is common in biochemistry. A reducing equivalent can be an electron or a hydrogen atom as a hydride ion. Reductants in chemistry are very diverse. Electropositive elemental metals, such as lithium, sodium, magnesium, iron, zinc, and aluminium, are good reducing agents. These metals donate electrons relatively readily. Hydride transfer reagents, such as NaBH4 and LiAlH4, reduce by atom transfer: they transfer the equivalent of hydride or H−. These reagents are widely used in the reduction of carbonyl compounds to alcohols.
Trialkylaluminium compounds can exist as either monomers or dimers, depending on the steric bulk of the groups attached. For example, trimethylaluminium exists as a dimer, but trimesitylaluminium adopts a monomeric structure.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.